Most recent articles by:

Editorial Team

- Advertisement -

Repair Biotechnologies to Leverage Genevant Sciences’ LNP Technology for Atherosclerosis Treatment

Repair Biotechnologies has joined forces with Swiss company Genevant Sciences to gain access to Genevant’s lipid nanoparticle (LNP) technology delivery system. Repair will specifically...

AbbVie’s Parkinson’s Drug Meets Phase 3 Trial Goal

AbbVie has disclosed that its late-stage monotherapy prospect substantially decreased the impact of the condition in patients as contrasted with placebo on the same...

AstraZeneca Expands AI-Powered Immuno-Oncology Research Partnership with Immunai

Immunai, a biotechnology company based in New York, has partnered with AstraZeneca in a multiyear endeavor to try and change the cancer immunotherapy trials...

FDA authorizes the first novel schizophrenia therapy in decades

The FDA gave the green light to Bristol Myers Squibb’s much-anticipated schizophrenia drug Cobenfy, the first new chemical entity to treat the severe, chronic...

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Health technology company PicnicHealth has launched a new product, Virtual Site, which allows researchers to carry out clinical trials remotely. This innovation is targeted...

Vicebio Raises $100 Million in Series B Funding to Advance RSV Combination Vaccine Through Phase I

Vicebio, the British biotech, has closed a $100 million Series B funding round as it advances a Phase I study of its bivalent vaccine...

Experimental Pill by Novo Nordisk Shown to Have Side Effects in Trial

Amycretin, Novo Nordisk's much-anticipated experimental weight-loss drug, was found to be safe in an early-stage trial, with mild to moderate side effects, the company...

Biogen and UCB’s lupus drug achieves primary objective in late-stage trial

Biogen and UCB have published a listing of a late-stage clinical trial of dapirolizumab pegol, an experimental drug for treating lupus, a disease in...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm
- Advertisement -